Literature DB >> 16133665

Predictive value of the time-intensity curves on dynamic contrast-enhanced magnetic resonance imaging for lymphatic spreading in breast cancer.

Shuhei Komatsu1, Chol Joo Lee, Daisuke Ichikawa, Takashi Hamashima, Noriaki Morofuji, Koichi Shirono, Yohei Hosokawa, Harumi Okabe, Hideaki Kurioka, Hisakazu Yamagishi, Takahiro Oka.   

Abstract

PURPOSE: Dynamic contrast-enhanced magnetic resonance imaging (CE-MRI) has emerged as a promising diagnostic modality in various breast cancer treatments. However, little is known about the correlation between the pattern of time to signal intensity curves (TIC) on the CE-MRI and clinicopathologic features. This study was designed to investigate these correlations and evaluate the predictive value of TIC on CE-MRI in order to identify high-risk patients.
METHODS: Between 2001 and 2003, 101 lesions were evaluated to detect malignancy on CE-MRI in 101 women who were suspected of having breast tumors based on either clinical findings or conventional imaging studies. Moreover, the clinicopathologic findings were compared with the pattern of TIC for the 69 surgically treated malignant lesions.
RESULTS: In detecting malignancy, the sensitivity, specificity, and accuracy were 78.7%, 88.5%, and 81.2%, respectively, in the 101 breast lesions. Especially for the 69 surgically treated malignant lesions, in comparison with breast cancer tumors with the benign pattern of TIC, the breast cancer tumors with a malignant pattern were found more frequently in lymphatic invasion (P < 0.01) and lymph node metastasis (P < 0.005), although no statistical correlation regarding the histological type, tumor size, vascular invasion, extensive intraductal component, hormone receptor status, or pathological stage was noted between the two groups. According to a logistic regression model, lymph node metastasis was found to be a significant independent variable.
CONCLUSION: The pattern of TIC could be used to predict lymphatic spreading associated with lymph node metastasis prior to surgery as well as to detect malignancy. Therefore, a more detailed evaluation should be made to identify the presence of lymphatic spreading in patients with a malignant pattern of TIC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133665     DOI: 10.1007/s00595-005-3032-5

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  19 in total

Review 1.  Dynamic image interpretation of MRI of the breast.

Authors:  C K Kuhl; H H Schild
Journal:  J Magn Reson Imaging       Date:  2000-12       Impact factor: 4.813

2.  Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors.

Authors:  E Furman-Haran; R Margalit; D Grobgeld; H Degani
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

3.  Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI.

Authors:  D L Buckley; P J Drew; S Mussurakis; J R Monson; A Horsman
Journal:  J Magn Reson Imaging       Date:  1997 May-Jun       Impact factor: 4.813

4.  Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features.

Authors:  P C Stomper; S Herman; D L Klippenstein; J S Winston; S B Edge; M A Arredondo; R V Mazurchuk; L E Blumenson
Journal:  Radiology       Date:  1995-11       Impact factor: 11.105

5.  MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation.

Authors:  S E Harms; D P Flamig; K L Hesley; M D Meiches; R A Jensen; W P Evans; D A Savino; R V Wells
Journal:  Radiology       Date:  1993-05       Impact factor: 11.105

6.  Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis.

Authors:  L D Buadu; J Murakami; S Murayama; N Hashiguchi; S Sakai; K Masuda; S Toyoshima; S Kuroki; S Ohno
Journal:  Radiology       Date:  1996-09       Impact factor: 11.105

7.  Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer.

Authors:  M E Van Hoef; W F Knox; S S Dhesi; A Howell; A M Schor
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee.

Authors:  L Nyström; L G Larsson; L E Rutqvist; A Lindgren; M Lindqvist; S Rydén; I Andersson; N Bjurstam; G Fagerberg; J Frisell
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

9.  Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density.

Authors:  C F van Dijke; R C Brasch; T P Roberts; N Weidner; A Mathur; D M Shames; J S Mann; F Demsar; P Lang; H C Schwickert
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

10.  Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen.

Authors:  Y Ogawa; Y S Chung; B Nakata; S Takatsuka; K Maeda; T Sawada; Y Kato; K Yoshikawa; M Sakurai; M Sowa
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

View more
  3 in total

Review 1.  Imaging the lymphatic system.

Authors:  Lance L Munn; Timothy P Padera
Journal:  Microvasc Res       Date:  2014-06-21       Impact factor: 3.514

2.  Design study of a high-resolution breast-dedicated PET system built from cadmium zinc telluride detectors.

Authors:  Hao Peng; Craig S Levin
Journal:  Phys Med Biol       Date:  2010-04-19       Impact factor: 3.609

3.  Development of a risk-stratification scoring system for predicting lymphovascular invasion in breast cancer.

Authors:  Ma-Yi-di-Li Ni-Jia-Ti; Di-Li-A-Re-Mu Ai-Hai-Ti; Ai-Si-Ka-Er-Jiang Huo-Jia; Pa-Li-Dan-Mu Wu-Mai-Er; A-Bu-du-Ke-You-Mu-Jiang A-Bu-Li-Zi; Yu Shi; Nu-Er-A-Mi-Na Rou-Zi; Wen-Jing Su; Guo-Zhao Dai; Mai-He-Mi-Ti-Jiang Da-Mo-la
Journal:  BMC Cancer       Date:  2020-02-03       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.